Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Bouchlaka, Myriam N ^a   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Cancer immunotherapy; Inflammation; Macrophage; Organ damage; Pro inflammatory cytokines; TNF

Indexed keywords

CD40 ANTIBODY; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; IPILIMUMAB; MONOCLONAL ANTIBODY; SIPULEUCEL T; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

AGING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MODEL; GERIATRIC PATIENT; HUMAN; INFLAMMATORY DISEASE; LETHALITY; LIVER TOXICITY; MACROPHAGE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE ORGAN FAILURE; NEOPLASM; NONHUMAN; TREATMENT OUTCOME;

EID: 84894569022     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27186     Document Type: Article

References (10)

1. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83-117; PMID:19007331; http://dx.doi.org/10.1146/ annurev.immunol.021908.132544
2. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol 2002; 3:289-97; PMID:12067806; http://dx.doi.org/10.1016/S1470-2045(02)00730-1
3. Brüünsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003; 23:15-39; PMID:12645876; http:// dx.doi.org/10.1016/S0889-8561(02)00056-5
4. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL. The origins of age-related proinflammatory state. Blood 2005; 105:2294-9; PMID:15572589; http://dx.doi. org/10.1182/blood-2004-07-2599
5. Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992; 51:1953-6; PMID:1453878; http://dx.doi.org/10.1016/0024-3205(92)90112-3
6. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004; 39:687-99; PMID:15130663; http://dx.doi. org/10.1016/j.exger.2004.01.009
7. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 2003; 170:2727-33; PMID:12594303
8. Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, Wilkins DE, Alderson KL, Hsiao HH, Weiss JM, et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med 2013; 210:2223- 37; PMID:24081947; http://dx.doi.org/10.1084/ jem.20131219
9. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 2008; 13:5094-107; PMID:18508572; http://dx.doi. org/10.2741/3066
10. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9:361-71; PMID:19343034; http://dx.doi.org/10.1038/nrc2628